Loading BDX detail
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Chart data unavailable

Becton, Dickinson, and Company is a cheap dividend stock that may become even cheaper in a market crash. Given Intuitive Surgical's prospects in its core market, the stock would be a no-brainer in a downturn.

FRANKLIN LAKES, N.J., April 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.

FRANKLIN LAKES, N.J., April 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Richard (Rick) Byrd has informed the company of his intent to retire after nearly 25 years with BD.

BDX seeks CE Mark for its Liverty TIPS Stent Graft, a next-gen device aimed at improving portal hypertension treatment and expanding its European footprint.

New study findings published in the Journal of Clinical Medicine highlight the ease of use and comfort of BD PureWick® Female External Catheter can support a better night's rest FRANKLIN LAKES, N.J. , April 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new clinical findings revealing that women managing nighttime urinary incontinence reported better sleep and greater overall comfort when using the BD PureWick® Urine Collection System.

BDX launches HemoSphere Stream, enabling continuous non-invasive BP monitoring and boosting its advanced patient monitoring portfolio.

CE Marking and ARCH clinical trial data position the Liverty™ TIPS Stent Graft to expand treatment options for patients with advanced liver disease FRANKLIN LAKES, N.J., April 8, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced application of CE Mark for the Liverty™ TIPS Stent Graft, delivering innovation to portal hypertension care across the European Union.

We bought four “new” holdings in the quarter. Two of the four — Blackstone and Otis — we have owned before. In IT, we exited Oracle and trimmed Broadcom. Our five-year investment in Oracle proved highly profitable as the company transitioned its business model from licensing to software-as-a-service. On the semiconductor side, we modestly reduced our position in Broadcom to fund our new investment in Taiwan Semiconductor.

New HemoSphere Stream™ Module expands access to continuous, noninvasive arterial waveform data across compatible bedside monitors and broader care settings, giving more clinicians real-time insight into more patients. FRANKLIN LAKES, N.J.

BDX rolls out AI-powered Pyxis Pro and Incada platforms in Europe, aiming to boost hospital efficiency, improve medication access and elevate patient care.

/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), empresa líder mundial en tecnología médica, anunció hoy el lanzamiento en Europa de la solución

/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), ein weltweit führendes Medizintechnikunternehmen, gab heute die Einführung der BD Pyxis Pro

/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), l'une des principales entreprises mondiales de technologie médicale, a annoncé aujourd'hui le

/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD Pyxis Pro

Advanced automation and connected data capabilities strengthen medication inventory control and enhance safety across pharmacy settings. FRANKLIN LAKES, N.J.